December 15, 2011

Polytherapeutics filed United States and PCT International patent applications pertaining to compositions and method for transdermal administration of non-steroidal anti-inflammatory and analgesic drug (NSAID) for the treatment of inflammation and pain caused by conditions such as arthritis, degenerative joint disease, and minor pains. The patent filings cover PHARMAGESIC™ TRANSDERMAL SYSTEM, a new product developed at Polytherapeutics. Pharmagesic™ is comprised of an NSAID diclofenac sodium in a PharmaDur® gel matrix for topical skin application. This product forms an invisible and imperceptible “Virtual Patch” on skin and provides and provides 24-hour delivery of the drug with a single dose application. Key benefits of Pharmagesic™ include sustained therapeutic activity, minimization of gastrointestinal tract irritation, and potentially lower systemic toxicity risks, which are inherent to NSAID therapy.